Trial reportJournal of materials science. Materials in medicine2025
Mineralized collagen-enhanced bone cement: A prospective, randomized controlled trial in total knee arthroplasty.
Trial report in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A narrative review of clinical research on knee osteoarthritis in 2025.Annals of joint · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Total knee arthroplasty (TKA) is a common procedure for end-stage osteoarthritis (OA). Traditional polymethylmethacrylate (PMMA) bone cement used in TKA has limitations, including lack of osteointegration and higher modulus than bone. We developed a novel bone cement, mineralized collagen (MC)-PMMA, to address these issues. In a prospective, randomized controlled trial, we compared TKA outcomes using MC-PMMA versus traditional PMMA (T-PMMA) in 34 patients with bilateral late-stage osteoarthritis. Evaluated parameters included patient-reported outcome measures (PROMs), knee range of motion, pain scores, complications, and radiographic evaluations over a 45.8-month follow-up. The MC-PMMA group showed significantly improved Knee Society function scores at one-year follow-up. No significant differences were found between groups in other PROMs, knee range of motion, or pain scores. Radiographic evaluations revealed no differences in postoperative Hip-Knee-Ankle (HKA) angle, anatomical axis angle, or radiolucent lines. Complication rates were similar, with no infections, aseptic loosening, peri-prosthetic fractures, or revisions. MC-PMMA is a promising biomaterial for TKA, offering comparable safety and mid-term clinical outcomes to T-PMMA. Its use may lead to earlier functional recovery, highlighting the potential of nanomaterials in orthopedic applications. Trial registration number: ChiCTR1800014811 (02/07/2018).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.